First phase II/III study of REM-001 for the treatment of cutaneous (skin surface) metastatic breast cancer (CMBC).
Phase of Trial: Phase II/III
Latest Information Update: 11 Jan 2016
At a glance
- Drugs REM 001 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Jan 2016 New trial record
- 05 Jan 2016 According to a Adgero Biopharmaceuticals, results at the 8th Annual Biotech Showcase conference.